权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Tickborne SFTS Virus Vaccine Development

蜱传 SFTS 病毒疫苗开发

基本信息

批准号：
10670989
负责人：
Jae U Jung
金额：
$ 56.45万
依托单位：
CLEVELAND CLINIC LERNER COM-CWRU
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-08-03 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10670989
关键词：
4 year old Age Antibody Response Asia Attenuated Attenuated Vaccines Basic Science Biochemical CNR1 gene Cells Characteristics Clinical Communicable Diseases DNA DNA Vaccines Dangerousness Disease Outbreaks Epidemic Family Far East Ferrets Ferritin Fever Future Genes Genetic Genome Genotype Genus Phlebovirus Glycoproteins Goals Head Hemorrhage Host Defense Human IFNAR1 gene Immune Immune Evasion Immunity Immunocompetent Immunologics Incidence Infection Interleukin-10 MAP3K8 gene Modeling Molecular Morbidity - disease rate Mus Pathogenesis Pathogenicity Pathway interactions Patients Persons Phosphotransferases Production Proteins RNA RNA-Directed RNA Polymerase Recombinant Proteins Recombinants Risk Factors Seroprevalences Severe Fever with Thrombocytopenia Syndrome Virus Source Surface Symptoms Syndrome System T cell response Testing Thrombocytopenia Ticks Time Vaccination Vaccine Design Vaccines Vesicular stomatitis Indiana virus Viral Viral Genes Viral Genome Viral Hemorrhagic Fevers Viral Pathogenesis Viral Proteins Virion Virus Virus Diseases Virus Replication age group age related aged clinical diagnosis clinically relevant comparative gene function immunogenicity in vivo insight interferon alpha receptor member mortality mouse model mutant nanobiotechnology nanoparticle neutralizing antibody older patient outbreak concern pathogenic virus protective efficacy recombinant virus reverse genetics tick-borne tool vaccine candidate vaccine development vaccine efficacy vector vaccine

项目摘要

Project Summary/Abstract Severe fever with thrombocytopenia syndrome (SFTS) is a newly emerging tick-borne infectious disease caused by SFTS virus (SFTSV). SFTSV is listed in the most dangerous viral pathogens by the WHO that most likely cause wide epidemics in the near future. The incidence of SFTSV infection has continuously increased up to more than 5,000 humans with a mortality rate ranging from 12% to as high as 30%. SFTSV induces a characteristic thrombocytopenia that is remarkably similar to viral hemorrhagic fevers. Infected ticks are the major source of human SFTSV infection. Particularly, the recent spread of this tick to over 12 states of USA increases the potential for outbreaks of the disease beyond the Far East Asia. The sero-prevalence of SFTSV in healthy people is not significantly different among age groups, but clinically diagnosed SFTS patients are older than ~50 years, suggesting that age is the critical risk factor for SFTS morbidity and mortality. No effective vaccines are currently available for SFTSV. The goal of this proposal is to comprehensively test and compare the immunogenicity and protection efficacy of four SFTSV- specific vaccine candidates against lethal SFTSV infection in age-dependent ferret model.

项目总结/摘要严重发热伴血小板减少综合征（SFTS）是一种新出现的蜱传由SFTS病毒（SFTSV）引起的传染病。SFTSV被列为最危险的病毒这些病原体很可能在不久的将来引起广泛的流行。的发生率 SFTSV感染已持续增加至5，000多人，死亡率为从12%到高达30%不等。SFTSV诱导特征性血小板减少症，与病毒性出血热非常相似受感染的蜱是人类SFTSV的主要来源感染特别是，最近这种蜱传播到美国12个州，在远东以外地区爆发疫情健康人群中SFTSV的血清流行病学调查不同年龄组的人之间没有显著差异，但临床诊断的SFTS患者年龄大于50岁，表明年龄是SFTS发病率和死亡率的关键危险因素。目前没有有效的疫苗可用于SFTSV。本提案的目的是全面测试和比较了4株SFTSV的免疫原性和保护效力，在年龄依赖性雪貂模型中针对致死性SFTSV感染特异性疫苗候选物。